
News|Articles|November 29, 2012
Study: Similar safety, efficacy with dabigatran versus warfarin in diabetic patients with Afib
Patients with nonvalvular atrial fibrillation (NVAF) who also have diabetes experienced similar safety and efficacy with dabigatran etexilate mesylate (Pradaxa) 150 mg or dabigatran 110 mg relative to warfarin, in comparison to patients without diabetes who have NVAF, according to data presented at American Heart Association's Scientific Sessions 2012.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Insights from the AMCP Nexus 2025 Meeting
2
Clinical and Economic Impact of OAB Symptoms in Men Receiving Pharmacological Treatment for BPH
3
The Shift in Star Ratings That Health Plans Can't Ignore
4
MHE Week in Review – HPV Vaccine Still Effective, Dry Eye Disease Lacks Effective Treatments and More
5

















































